Top

Published in:

Open Access 01-12-2012 | Research article

Alterations of global histone H4K20 methylation during prostate carcinogenesis

Authors: Turang E Behbahani, Philip Kahl, Johannes von der Gathen, Lukas C Heukamp, Claudia Baumann, Ines Gütgemann, Bernhard Walter, Ferdinand Hofstädter, Patrick J Bastian, Alexander von Ruecker, Stefan C Müller, Sebastian Rogenhofer, Jörg Ellinger

Published in: BMC Urology | Issue 1/2012

Abstract

Background

Global histone modifications have been implicated in the progression of various tumour entities. Our study was designed to assess global methylation levels of histone 4 lysine 20 (H4K20me1-3) at different stages of prostate cancer (PCA) carcinogenesis.

Methods

Global H4K20 methylation levels were evaluated using a tissue microarray in patients with clinically localized PCA (n = 113), non-malignant prostate disease (n = 27), metastatic hormone-naive PCA (mPCA, n = 30) and castration-resistant PCA (CRPC, n = 34). Immunohistochemistry was performed to assess global levels of H4K20 methylation levels.

Results

Similar proportions of the normal, PCA, and mPCA prostate tissues showed strong H4K20me3 staining. CRPC tissue analysis showed the weakest immunostaining levels of H4K20me1 and H4K20me2, compared to other prostate tissues. H4K20me2 methylation levels indicated significant differences in examined tissues except for normal prostate versus PCA tissue. H4K20me1 differentiates CRPC from other prostate tissues. H4K20me1 was significantly correlated with lymph node metastases, and H4K20me2 showed a significant correlation with the Gleason score. However, H4K20 methylation levels failed to predict PSA recurrence after radical prostatectomy.

Conclusions

H4K20 methylation levels constitute valuable markers for the dynamic process of prostate cancer carcinogenesis.

Available only for authorised users

Chen Z, Wang L, Wang Q, Li W: Histone modifications and chromatin organization in prostate cancer. Epigenomics. 2010, 2: 551-560. 10.2217/epi.10.31.CrossRefPubMedPubMedCentral

Li LC, Carroll PR, Dahiya R: Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst. 2005, 97: 105-113.CrossRef

Kouzarides T: Chromatin modifications and their function. Cell. 2007, 128: 693-705. 10.1016/j.cell.2007.02.005.CrossRefPubMed

Schotta G, Sengupta R, Kubicek S, Malin S, Kauer M, Callén E, Celeste A, Pagani M, Opravil S, De La Rosa-Velazquez IA, Espejo A, Bedford MT, Nussenzweig A, Busslinger M, Jenuwein T: A chromatin-wide transition to H4K20 mono-methylation impairs genome integrity and programmed DNA rearrangements in the mouse. Genes Dev. 2008, 22: 2048-2061. 10.1101/gad.476008.CrossRefPubMedPubMedCentral

Botuyan MV, Lee J, Ward IM, Kim JE, Thompson JR, Chen J, Mer G: Structural basis for the methylation state-specific recognition of histone H4-K20 by 53BP1 and Crb2 in DNA repair. Cell. 2006, 127: 1361-1373. 10.1016/j.cell.2006.10.043.CrossRefPubMedPubMedCentral

Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Perez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T, Esteller M: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005, 37: 391-400. 10.1038/ng1531.CrossRefPubMed

Pogribny IP, Ross SA, Tryndyak VP, Pogribna M, Poirier LA, Karpinets TV: Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats. Carcinogenesis. 2006, 27: 1180-1186. 10.1093/carcin/bgi364.CrossRefPubMed

Tryndyak VP, Kovalchuk O, Pogribny IP: Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins. Cancer Biol Ther. 2006, 5: 65-70. 10.4161/cbt.5.1.2288.CrossRefPubMed

Schneider AC, Heukamp LC, Rogenhofer S, Fechner G, Bastian PJ, von Ruecker A, Müller SC, Ellinger J: Global histone H4K20 trimethylation predicts cancer-specific survival in patients with muscle invasive bladder cancer. BJU Int.

10.

Seligson DB, Horvath S, McBrian MA, Yu H, Tze S, Grunstein M, Kurdistani SK: Global levels of histone modifications predict prognosis in different cancers. Am J Pathol. 2009, 174: 1619-1628. 10.2353/ajpath.2009.080874.CrossRefPubMedPubMedCentral

11.

Ellinger J, Kahl P, Mertens C, Rogenhofer S, Hauser S, Hartmann W, Bastian PJ, Buettner R, Mueller SC, von Ruecker SC: Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. Int J Cancer. 2010, 127: 2360-2366. 10.1002/ijc.25250.CrossRefPubMed

12.

Ellinger J, Kahl P, von der Gathen J, Rogenhofer S, Heukamp LC, Gutgemann I, Walter B, Hofstädter F, Buttner R, Mueller SC, Bastian PJ, von Ruecker A: Global levels of histone modifications predict prostate cancer recurrence. Prostate. 2010, 70: 61-69. 10.1002/pros.21038.CrossRefPubMed

13.

Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK: Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005, 435: 1262-1266. 10.1038/nature03672.CrossRefPubMed

14.

Van den Broeck A, Bramilla E, Moro-Sibilot D, Lantuejoul S, Brambilla C, Eymin B, Khochbin S, Gazzeri S: Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Non-Small Cell Lung Cancer. Clin Cancer Res. 2008, 14: 7237-7245. 10.1158/1078-0432.CCR-08-0869.CrossRefPubMed

15.

Tsang LK, Hu N, Underhill DA: Comparative Analyses of SUV420H1 Isoforms and SUV420H2 Reveal Differences in Their Cellular Localization and Effects on Myogenic Differentiation. PLoS One. 2010, 5: e14447-10.1371/journal.pone.0014447.CrossRefPubMedPubMedCentral

16.

Zhou LX, Li T, Huang YR, Sha JJ, Sun P, Li D: Application of histone modification in the risk prediction of the biochemical recurrence after radical prostatectomy. Asian Journal of Andrology. 2010, 12: 171-179. 10.1038/aja.2009.81.CrossRefPubMed

17.

Ellinger J, Kahl P, von der Gathen J, Heukamp LC, Gütgemann I, Walter B, Hofstädter F, Bastian PJ, von Ruecker A, Müller SC, Rogenhofer S: Global Histone H3K27 Methylation Levels are Different in Localized and Metastatic Prostate Cancer. Cancer Invest.

18.

Freedland SJ: Screening, risk assessment, and the approach to therapy in patients with prostate cancer. Cancer. 2011, 117: 1123-1135. 10.1002/cncr.25477.CrossRefPubMed

19.

Kapoor-Vazirani P, Kagey JD, Vertino PM: SUV420H2 mediated H4K20 trimethylation enforces RNA polymerase II promoter-proximal pausing by blocking hMOF dependent H4K16 acetylation. Mol and Cell Biology. 2011, 8: 1594-1609.CrossRef

20.

Das PM, Ramachandran K, Vanwert J, Ferdinand L, Gopisetty G, Reis IM, Singal R: Methylation mediated silencing of TMS1/ASC gene in prostate cancer. Mol Cancer. 2006, 18: 28-CrossRef

21.

Suzuki M, Shigematsu H, Shivapurkar N, Reddy J, Miyajima K, Takahashi K, Gazdar AF, Frenkel EP: Methylation of apoptosis related genes in the pathogenesis and prognosis of Prostate cancer. Cancer Let. 2006, 242: 222-230. 10.1016/j.canlet.2005.11.002.CrossRef

22.

Balakrishnan L, Milavetz B: Decoding the histone H4 lysine 20 methylation mark. Crit Rev Biochem Mol Bio. 2010, 45: 440-452. 10.3109/10409238.2010.504700.CrossRef

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2490/12/5/prepub

Title: Alterations of global histone H4K20 methylation during prostate carcinogenesis
Authors: Turang E Behbahani
Philip Kahl
Johannes von der Gathen
Lukas C Heukamp
Claudia Baumann
Ines Gütgemann
Bernhard Walter
Ferdinand Hofstädter
Patrick J Bastian
Alexander von Ruecker
Stefan C Müller
Sebastian Rogenhofer
Jörg Ellinger
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: BMC Urology / Issue 1/2012
Electronic ISSN: 1471-2490
DOI: https://doi.org/10.1186/1471-2490-12-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Alterations of global histone H4K20 methylation during prostate carcinogenesis

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Genetic variation in SPAG16 regions encoding the WD40 repeats is not associated with reduced sperm motility and axonemal defects in a population of infertile males

Content validity and test-retest reliability of patient perception of intensity of urgency scale (PPIUS) for overactive bladder

A mouse model for interstitial cystitis/painful bladder syndrome based on APF inhibition of bladder epithelial repair: a pilot study

Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia

Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia

Designing the selenium and bladder cancer trial (SELEBLAT), a phase lll randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium